Report / Paper metadata
Preclinical characterization and phase I results of TQB2102, a first-in-class HER2 biparatopic antibody-drug conjugate, in patients with advanced solid tumors.
A biomedical paper record. This page preserves its title, publication metadata and identifier, not the full article. The title alone does not establish the study findings or their clinical importance.
Limits
No clinical review has been performed. This record is not a treatment recommendation, eligibility confirmation or current availability guarantee.
- Kind
- Paper metadata